Home › Companies › ACLARIS THERAPEUTICS INC. › 2023-2024

ACLARIS THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.

4Ballot items
106Asset managers
510Fund votes
June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 4 items on ACLARIS THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 2 approved · 2 without a stated outcome.

Material dissent

Elect Director: Christopher Molineaux 64% of votes cast Outcome not stated Director under 80%
2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement 64% of votes cast Approved Under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2025-2026

Explore ACLARIS THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ACLARIS THERAPEUTICS INC.

These tallies are ACLARIS THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ACLARIS THERAPEUTICS INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Christopher Molineaux	29,165,764	--	--	16,154,877	12,468,248	64%	Not verified	—
Elect Director: Vincent Milano	42,267,754	--	--	3,052,887	12,468,248	93%	Not verified	—
2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement	29,025,583	16,273,816	21,242	--	12,468,248	64%	Approved	—
3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024	56,610,643	1,154,624	23,622	--	--	98%	Approved	—

Source: ACLARIS THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the ACLARIS THERAPEUTICS INC. 2023-2024 meeting

Each item below shows how the 106 asset managers that disclosed a ACLARIS THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Christopher Molineaux

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD

FOR: 29,165,764WITHHELD: 16,154,877

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Christopher Molineaux

ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Christopher Molineaux”): 29,165,764 for, 16,154,877 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 7,104,668 for, 3,788,377 withheld, 38,352 abstained.

FORWITHHOLD

FOR: 7,104,668ABSTAIN: 38,352WITHHOLD: 3,788,377

Largest asset managers voting on “Election of Directors: Christopher Molineaux” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,882,172	0	0	For
BlackRock	0	0	2,706,426	Withhold
Fidelity	2,114,216	0	0	For
Charles Schwab	0	0	419,704	Withhold
Equitable	0	0	186,273	Withhold
QUANTITATIVE MASTER SERIES LLC	0	0	115,378	Withhold
TIAA	0	0	97,857	Withhold
Lincoln Financial	0	0	57,200	Withhold
Pacific Life	25,112	0	22,969	Mixed
T. Rowe Price	47,442	0	0	For
AIG/SunAmerica	0	0	34,229	Withhold
Harbor ETF Trust	30,304	0	0	For
State Street	0	0	24,620	Withhold
Nationwide	0	0	21,071	Withhold
Blackstone Alternative Investment Funds	0	0	16,300	Withhold
Principal Exchange-Traded Funds	0	0	16,142	Withhold
ProShares	0	0	15,939	Withhold
SEI	0	0	15,900	Withhold
John Hancock	0	14,788	0	Abstain
Bridge Builder Trust	0	12,653	0	Abstain
DWS	0	0	10,759	Withhold
Jackson National	0	8,881	0	Abstain
Principal	0	0	8,732	Withhold
Calvert	0	0	6,900	Withhold
Guardian Variable Products Trust	4,400	0	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

2. Elect Director: Vincent Milano

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 42,267,754WITHHELD: 3,052,887

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: Election of Directors: Vincent Milano

ACLARIS THERAPEUTICS INC.’s own tally for this item (“Elect Director: Vincent Milano”): 42,267,754 for, 3,052,887 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 10,857,249 for, 63,237 withheld, 10,911 abstained.

FOR

FOR: 10,857,249ABSTAIN: 10,911WITHHOLD: 63,237

Largest asset managers voting on “Election of Directors: Vincent Milano” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset manager	For	Abstain	Withheld	Vote
Vanguard	4,882,172	0	0	For
BlackRock	2,706,426	0	0	For
Fidelity	2,114,216	0	0	For
Charles Schwab	419,704	0	0	For
Equitable	125,873	0	60,400	Mixed
QUANTITATIVE MASTER SERIES LLC	115,378	0	0	For
TIAA	97,857	0	0	For
Lincoln Financial	57,200	0	0	For
Pacific Life	48,081	0	0	For
T. Rowe Price	47,442	0	0	For
AIG/SunAmerica	34,229	0	0	For
Harbor ETF Trust	30,304	0	0	For
State Street	24,620	0	0	For
Nationwide	21,071	0	0	For
Blackstone Alternative Investment Funds	16,300	0	0	For
Principal Exchange-Traded Funds	16,142	0	0	For
ProShares	15,939	0	0	For
SEI	15,900	0	0	For
John Hancock	14,788	0	0	For
Bridge Builder Trust	12,653	0	0	For
DWS	10,759	0	0	For
Jackson National	0	8,881	0	Abstain
Principal	8,732	0	0	For
Calvert	6,900	0	0	For
Guardian Variable Products Trust	4,400	0	0	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

3. 2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

64% Approved · of votes cast

FOR 64%AGAINST

FOR: 29,025,583AGAINST: 16,273,816

Details: description as filed, official tally, votes by 106 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.

ACLARIS THERAPEUTICS INC.’s own tally for this item (“2. The compensation of the Company's named executive officers, as disclosed in the Proxy Statement”): 29,025,583 for, 16,273,816 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 34 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Vanguard	4,882,172	0	For
BlackRock	0	2,706,426	Against
Fidelity	625,766	1,488,450	Mixed
Charles Schwab	0	419,704	Against
Equitable	0	186,273	Against
QUANTITATIVE MASTER SERIES LLC	0	115,378	Against
TIAA	0	97,857	Against
Lincoln Financial	57,200	0	For
Pacific Life	25,112	22,969	Mixed
T. Rowe Price	0	47,442	Against
AIG/SunAmerica	0	34,229	Against
Harbor ETF Trust	30,304	0	For
State Street	24,620	0	For
Nationwide	0	21,071	Against
Blackstone Alternative Investment Funds	0	16,300	Against
Principal Exchange-Traded Funds	0	16,142	Against
ProShares	0	15,939	Against
SEI	0	15,900	Against
John Hancock	0	14,788	Against
Bridge Builder Trust	0	12,653	Against
DWS	0	10,759	Against
Jackson National	0	8,881	Against
Principal	0	8,732	Against
Calvert	0	6,900	Against
Guardian Variable Products Trust	4,400	0	For

Fund voting reports, all 34 managers: 5,652,947 for, 5,275,613 against, 2,837 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 80 asset managers voting on “To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset manager	For	Against	Vote
Bain Capital Life Sciences Investors, LLC	3,000,000	0	For
DE Shaw	0	2,857,900	Against
Rock Springs Capital Management LP	2,753,495	0	For
Two Sigma	0	1,726,873	Against
GEODE CAPITAL MANAGEMENT, LLC	0	1,565,250	Against
BlackRock	13,929	1,449,460	Against
State Street	1,132,475	16,861	For
ACADIAN ASSET MANAGEMENT LLC	0	700,735	Against
Samsara BioCapital, LLC	696,171	0	For
Fidelity	667,037	0	For
Ensign Peak Advisors, Inc	641,643	0	For
Palo Alto Investors LP	569,832	0	For
Northern Trust	541,822	3,742	For
Charles Schwab	0	419,704	Against
Citadel	393,993	0	For
MELLON INVESTMENTS Corp	0	345,256	Against
HighTower Advisors, LLC	0	300,990	Against
PNC BANK, NATIONAL ASSOCIATION	0	270,000	Against
STRS OHIO	0	264,700	Against
Aisling Capital Management LP	196,513	0	For
AQR	0	182,931	Against
BBR PARTNERS, LLC	180,000	0	For
Vanguard	129,049	0	For
T. Rowe Price	0	109,767	Against
Connor, Clark & Lunn Investment Management Ltd.	0	107,345	Against

Institutional-manager reports, all 80 managers: 10,999,078 for, 10,949,394 against. Showing the 25 largest; see all in the interactive database.

4. 3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 56,610,643AGAINST: 1,154,624

Details: description as filed, official tally, votes by 34 asset managers

Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of Aclaris Therapeutics, Inc. for its fiscal year ending December 31, 2024.

ACLARIS THERAPEUTICS INC.’s own tally for this item (“3. The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024”): 56,610,643 for, 1,154,624 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 34 asset managers below reported 10,928,560 for, 2,837 abstained.

FOR

FOR: 10,928,560ABSTAIN: 2,837

Largest asset managers voting on “To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the ” at ACLARIS THERAPEUTICS INC., 2023-2024
Asset manager	For	Vote
Vanguard	4,882,172	For
BlackRock	2,706,426	For
Fidelity	2,114,216	For
Charles Schwab	419,704	For
Equitable	186,273	For
QUANTITATIVE MASTER SERIES LLC	115,378	For
TIAA	97,857	For
Lincoln Financial	57,200	For
Pacific Life	48,081	For
T. Rowe Price	47,442	For
AIG/SunAmerica	34,229	For
Harbor ETF Trust	30,304	For
State Street	24,620	For
Nationwide	21,071	For
Blackstone Alternative Investment Funds	16,300	For
Principal Exchange-Traded Funds	16,142	For
ProShares	15,939	For
SEI	15,900	For
John Hancock	14,788	For
Bridge Builder Trust	12,653	For
DWS	10,759	For
Jackson National	8,881	For
Principal	8,732	For
Calvert	6,900	For
Guardian Variable Products Trust	4,400	For

Showing the 25 largest of 34 asset managers. See all 34 in the interactive database.

Largest ACLARIS THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,264,786 shares outstanding at the time of that meeting.

Fund voting reports: top ACLARIS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	6.85%
2	BlackRock	3.80%
3	Fidelity	2.97%
4	Charles Schwab	0.59%
5	Equitable	0.26%
6	QUANTITATIVE MASTER SERIES LLC	0.16%
7	TIAA	0.14%
8	Lincoln Financial	0.08%
9	Pacific Life	0.07%
10	T. Rowe Price	0.07%

Institutional-manager reports: top ACLARIS THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of our named executive officers, as…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Bain Capital Life Sciences Investors, LLC	4.21%
2	DE Shaw	4.01%
3	Rock Springs Capital Management LP	3.86%
4	Two Sigma	2.42%
5	GEODE CAPITAL MANAGEMENT, LLC	2.20%
6	BlackRock	2.05%
7	State Street	1.61%
8	ACADIAN ASSET MANAGEMENT LLC	0.98%
9	Samsara BioCapital, LLC	0.98%
10	Fidelity	0.94%

Reported ACLARIS THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ACLARIS THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
Vivo Opportunity Fund Holdings, L.P.	11.16%	13G
Vanguard Group	9.14%	13F
BlackRock	7.99%	13F
Morgan Stanley	5.72%	13F
D.E. Shaw	4.61%	13F
Millennium Management	4.59%	13F
Renaissance Technologies	2.35%	13F
Geode Capital	2.20%	13F
State Street	1.88%	13F
Two Sigma	1.87%	13F

Percentages above are of 71,264,786 shares outstanding, as reported by ACLARIS THERAPEUTICS INC. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACLARIS THERAPEUTICS INC.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At ACLARIS THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 106 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 510 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of our named executive officers, as… — ACLARIS THERAPEUTICS INC.'s filing reports the proposal as approved, with 64% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ACLARIS THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

ACLARIS THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.